Modified gaphene oxide (GO) particles in peptide hydrogels: a hybrid system enabling scheduled delivery of synergistic combinations of chemotherapeutics

Abstract

Composite material enabling the delivery of synergistic combination of doxorubicin and gemcitabine against breast cancer with molar and kinetic precision.

Advances in Drug Delivery Nanosystems Using Graphene-Based Materials and Carbon Nanotubes

“…Max8 hydrogel was found to release GEM faster, achieving a 10-fold molar ratio to DOX. The composite prepared by suspension of selected NPs of DOX loaded on modified GO in a GEM/Max8 hydrogel matrix was effective against a triple negative breast cancer cell line, MDA-MB-231, showing more powerful synergism compared to the combination of both free drugs co-administered in form of solution [190].…”

Peptide‐based hydrogels as delivery systems for doxorubicin

“…They and modified graphene oxide (GO) nanoparticles loaded with Dox. 85 The resulting composite material exhibits high loading of the two drugs and an optimal with a ratio of 10/1 between GEM and Dox that assure a synergistic combination of drugs. Moreover, the optimized formulation showed a faster kinetic release for GEM (47-fold rate)…”

Recent advancement in biomedical applications on the surface of two-dimensional materials: from biosensing to tissue engineering

“…220 A particular function of drug delivery systems is to perform the release of a sequence of drugs with defined kinetics and molar ratios to enhance the therapeutic effects while minimizing the dose to patients. 221 Recently, Schneible et al achieved this concept by developing a nanocomposite based on GO nanosheets embedded in a Max8 peptide hydrogel, which provides controlled kinetics and molar ratios of release of doxorubicin (DOX) and gemcitabine (GEM). 221 With this nanocomposite, the authors demonstrated a high DOX loading on GO and sustained release with pH (18.9% over 72 h and 31.4% over 4 weeks) and a Max8 hydrogel with a capability to release GEM with faster kinetics and with a 10-fold molar ratio to DOX.…”

“…221 Recently, Schneible et al achieved this concept by developing a nanocomposite based on GO nanosheets embedded in a Max8 peptide hydrogel, which provides controlled kinetics and molar ratios of release of doxorubicin (DOX) and gemcitabine (GEM). 221 With this nanocomposite, the authors demonstrated a high DOX loading on GO and sustained release with pH (18.9% over 72 h and 31.4% over 4 weeks) and a Max8 hydrogel with a capability to release GEM with faster kinetics and with a 10-fold molar ratio to DOX. The nanocomposite based on the DOX/GO@GEM/ Max8 hydrogel matrix was tested against a triple negative breast cancer cell line, MDA-MB-231, and achieved a combination index of 0.093 ± 0.001; indicating a much stronger synergistic effect compared to the DOX-GEM combination as free drugs co-administered in solution (CI = 0.396 ± 0.034).…”